Company:Bharat Biotech

From HandWiki
Bharat Biotech International Limited
TypePrivate
IndustryBiotechnology
Founded1996; 30 years ago (1996)
FounderDr.Krishna Ella
HeadquartersGenome Valley, Turakapally, Hyderabad, India
Area served
Worldwide
Key people
Dr.Krishna Ella (chairman & MD)
Products
  • ROTAVAC,[1]
  • TypbarTCV,[2]
  • Biopolio
  • Comvac
  • JENVAC
  • COVAXIN
RevenueIncrease ₹8,148 crore (US$1.1 billion) (FY22)[3]
Increase ₹2,895 crore (US$410 million) (FY22)[3]
SubsidiariesChiron Behring Vaccines [4]
Websitewww.bharatbiotech.com

Bharat Biotech International Limited (BBIL) is an Indian multinational biotechnology company based in Hyderabad, which is engaged in drug discovery, drug development, and the manufacture of vaccines, biotherapeutics, pharmaceuticals and healthcare products.[5]

Overview

Bharat Biotech has its manufacturing facility situated at Genome Valley, Hyderabad, India.[5] As of July 2020, the company has over 700 employees[6] and has a presence worldwide.[5]

The company has been responsible for developing an eco-friendly recombinant[7] and a naturally attenuated strain derived Rotavirus vaccine called ROTAVAC.[8][9] They were one of the first to develop vaccines for viral diseases like Chikungunya[10][11] and Zika.[12][13] The company also produces vaccines for Japanese Encephalitis,[14] influenza H1N1, Rabies.[15] Bharat Biotech has biosafety level 3 (BSL3) laboratories.[16]

It has developed the world's first tetanus-toxoid conjugated vaccine for Typhoid.[15]

Bharat Biotech has delivered over nine billion doses of vaccines globally as of May 2025, has over 145 global patents and a portfolio of over 19 vaccines, four biotherapeutics and registrations in over 125 countries.[15]

COVID-19 vaccine development

See also: Medicine:Covaxin, BBV154, and COVID-19 vaccine

In April 2020, the company announced that they have partnered with US-based company FluGen and University of Wisconsin-Madison to develop a COVID-19 vaccine.[17][18]

A 5ml vial of Covaxin

In May 2020, Indian Council of Medical Research's (ICMR's) National Institute of Virology approved and provided the virus strains for developing a fully indigenous COVID-19 vaccine.[19][20] On June 29, 2020, the company got permission to conduct Phase 1 and Phase 2 clinical trials in India for a developmental COVID-19 vaccine named Covaxin, from the Drugs Controller General of India (DCGI), Government of India.[21][22][23][24] The Central Drugs Laboratory (CDL) at Kasauli in Himachal Pradesh has been engaged in testing experimental batches of Bharat Biotech's COVID-19 vaccine Covaxin on a priority basis.[25] A total of 12 sites were selected by the Indian Council for Medical Research for Phase I and II randomised, double-blind and placebo-controlled clinical trials of vaccine candidate.[26][27]

In September 2020, the company announced that it was going to manufacture the novel chimp-adenovirus, a single dose intranasal vaccine (codenamed BBV154) for COVID-19 being developed in collaboration with the American company Precision virologics[28] and Washington University School of Medicine in St. Louis, Missouri. It is currently undergoing clinical trials.[29][30] On October 12, 2021, Bharat Biotech's Covaxin got approved for usage on children between 2 and 18 years of age.[31]

Attempted data theft

In March 2021, Reuters reported that Chinese state-backed cyber-espionage group Red Apollo targeted Bharat Biotech's intellectual property for exfiltration.[32]

Vaccine Trials

On May 21, 2025, Bharat Biotech successfully completed Phase III clinical trials of its oral cholera vaccine, Hillchol, demonstrating efficacy against both Ogawa and Inaba serotypes.[15] The findings of the study have been published in the ScienceDirect vaccine journal.[15]

See also

References

  1. ↑ "WHO prequalifies new rotavirus vaccine". https://www.who.int/medicines/news/2018/prequalified_new-rotavirus_vaccine/en/. 
  2. ↑ "WHO recommends use of first typhoid conjugate vaccine". https://www.who.int/immunization/newsroom/press/who_recommends_use_first_typhoid_conjugate_vaccine/en/. 
  3. ↑ 3.0 3.1 "Bharat Biotech International Limited: Ratings reaffirmed". ICRA. https://www.icra.in/Rationale/ShowRationaleReport?Id=118785. 
  4. ↑ "Bharat Biotech buys Chiron Behring Vaccines from GSK" (in en). 15 February 2019. https://www.thehindubusinessline.com/companies/bharat-biotech-buys-chiron-behring-vaccines-from-gsk/article26279438.ece. 
  5. ↑ 5.0 5.1 5.2 "Bharat Biotech International Ltd". https://www.bloomberg.com/profile/company/7535940Z:IN. 
  6. ↑ "Leading Biotech Vaccine Manufacturers in India - Bharat Biotech". https://www.bharatbiotech.com/overview.html. 
  7. ↑ "Process for the preparation and purification of recombinant proteins" (in en). US patent No US8956812B2. 23 August 2004. https://patents.google.com/patent/US8956812B2/en. 
  8. ↑ Bhandari, Nita; Rongsen-Chandola, Temsunaro; Bavdekar, Ashish; John, Jacob; Antony, Kalpana; Taneja, Sunita; Goyal, Nidhi; Kawade, Anand et al. (June 2014). "Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial". The Lancet 383 (9935): 2136–2143. doi:10.1016/S0140-6736(13)62630-6. PMID 24629994. 
  9. ↑ Kang, G (October 2006). "Rotavirus vaccines.". Indian Journal of Medical Microbiology 24 (4): 252–7. doi:10.1016/S0255-0857(21)02284-2. PMID 17185842. 
  10. ↑ "Bharat Biotech's Zika, Chikungunya vaccines to enter Phase II trials; focus now on private label market". Moneycontrol. https://www.moneycontrol.com/news/business/companies/bharat-biotechs-zika-chikungunya-vaccines-to-enter-phase-ii-trials-focus-now-on-private-label-market-3633391.html. 
  11. ↑ "CEPI, 치쿤구니아 백신 개발 위해 국제백신연구소-바라트 바이오텍 컨소시엄에 최대 1410만달러 지원" (in ko). CEPI, 치쿤구니아 백신 개발 위해 국제백신연구소-바라트 바이오텍 컨소시엄에 최대 1410만달러 지원 - 뉴스와이어. 3 June 2020. https://www.newswire.co.kr/newsRead.php?no=905832. 
  12. ↑ "Bharat Biotech gets breakthrough in developing Zika vaccine". The Economic Times. 4 February 2016. https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bharat-biotech-gets-breakthrough-in-developing-zika-vaccine/articleshow/50835450.cms?from=mdr. 
  13. ↑ "CEPI awards up to US$14.1million to consortium of IVI and Bharat Biotech to advance development of Chikungunya vaccine in collaboration with Ind-CEPI – IVI". International Vaccine Institute. 3 June 2020. https://www.ivi.int/cepi-awards-up-to-us14-1million-to-consortium-of-ivi-and-bharat-biotech-to-advance-development-of-chikungunya-vaccine-in-collaboration-with-ind-cepi/. 
  14. ↑ Singh, Anit; Mitra, Monjori; Sampath, Gadey; Venugopal, P.; Rao, J. Venkateswara; Krishnamurthy, B.; Gupta, Mukesh Kumar; Sri Krishna, S. et al. (1 September 2015). "A Japanese Encephalitis Vaccine From India Induces Durable and Cross-protective Immunity Against Temporally and Spatially Wide-ranging Global Field Strains". Journal of Infectious Diseases 212 (5): 715–725. doi:10.1093/infdis/jiv023. PMID 25601942. 
  15. ↑ 15.0 15.1 15.2 15.3 15.4 "Bharat Bio successfully completes Phase III trials of new oral cholera vaccine Hillchol". The Times of India. 2025-05-21. ISSN 0971-8257. https://timesofindia.indiatimes.com/india/bharat-bio-successfully-completes-phase-iii-trials-of-new-oral-cholera-vaccine-hillchol/articleshow/121322323.cms. 
  16. ↑ "Slow off the starting blocks for Bharat Biotech's Covaxin mass production". 17 May 2021. https://www.newindianexpress.com/nation/2021/may/17/slow-off-the-starting-blocks-for-bharat-biotechscovaxin-mass-production-2303416.html. 
  17. ↑ "UW-Madison, Flugen, Bharat Biotech to develop coroflu, a coronavirus vaccine". https://ghi.wisc.edu/uw-madison-flugen-bharat-biotech-to-develop-coroflu-a-coronavirus-vaccine/. 
  18. ↑ "Bharat Biotech ties up with US varsity for Covid vaccine" (in en). Hindustan Times. 20 May 2020. https://www.hindustantimes.com/india-news/bharat-biotech-ties-up-with-us-varsity-for-covid-vaccine/story-dyJPOzW2G2rXcwsa9XV3tL.html. 
  19. ↑ "ICMR teams up with Bharat Biotech to develop Covid-19 vaccine" (in en). Livemint. 9 May 2020. https://www.livemint.com/news/india/icmr-teams-up-with-bharat-biotech-to-develop-covid-19-vaccine-11589038719666.html. 
  20. ↑ Chakrabarti, Angana (10 May 2020). "India to develop 'fully indigenous' Covid vaccine as ICMR partners with Bharat Biotech". ThePrint. https://theprint.in/health/india-to-develop-fully-indigenous-covid-vaccine-as-icmr-partners-with-bharat-biotech/418180/. 
  21. ↑ "India's First COVID-19 Vaccine Candidate Approved for Human Trials". The New York Times. 29 June 2020. https://www.nytimes.com/reuters/2020/06/29/world/asia/29reuters-health-coronavirus-india-vaccine.html. 
  22. ↑ "Human trial of India coronavirus vaccine announced". BBC News. 30 June 2020. https://www.bbc.com/news/world-asia-india-53230607. 
  23. ↑ "Bharat Biotech's Covid vaccine 1st in India to get approval for human trials" (in en). The Indian Express. 30 June 2020. https://indianexpress.com/article/india/bharat-biotechs-covid-vaccine-1st-in-india-to-get-approval-for-human-trials-6482403/. 
  24. ↑ "Covaxin: India's first COVID19 vaccine candidate from Bharat Biotech to begin human trials; check details". The Financial Express. 30 June 2020. https://www.financialexpress.com/lifestyle/health/covaxin-bharat-biotech-coronavirus-vaccine-india-first-covid19-vaccine-latest-updates/2008500/. 
  25. ↑ "Bharat Biotech COVID-19 vaccine: Testing underway at CDL-Kasauli, volunteer enrolment begins". Moneycontrol. https://www.moneycontrol.com/news/trends/health-trends/bharat-biotech-covid-19-vaccine-testing-underway-at-cdl-kasauli-volunteer-enrolment-begins-5529041.html. 
  26. ↑ "Human clinical trials of potential Covid-19 vaccine 'COVAXIN' started at AIIMS". DD News (Prasar Bharati, Ministry of I & B, Government of India). 25 July 2020. http://ddnews.gov.in/health/human-clinical-trials-potential-covid-19-vaccine-%E2%80%98covaxin%E2%80%99-started-aiims. 
  27. ↑ "Delhi: 30-year-old is first to get dose of trial drug Covaxin" (in en). The Indian Express. 25 July 2020. https://indianexpress.com/article/india/aiims-administers-first-dose-of-bharat-biotechs-potential-covid-vaccine-to-30-yr-old-man-6521778/. 
  28. ↑ "COVID-19 | Office of Technology Management/Tech Transfer | Washington University in St. Louis". https://otm.wustl.edu/category/covid-19/. 
  29. ↑ "Bharat Biotech to make a billion doses of an intranasal adenovirus vaccine" (in en). The Indian Express. 23 September 2020. https://indianexpress.com/article/india/bharat-biotech-to-manufacture-a-billion-doses-of-nasal-spray-covid-19-vaccine-6607305/. 
  30. ↑ "Bharat Biotech Partners With US University For Covid Intranasal Vaccine". NDTV.com. https://www.ndtv.com/india-news/bharat-biotech-partners-with-us-university-for-covid-intranasal-vaccine-2299947. 
  31. ↑ "COVID-19: Covaxin Vaccine Approved For Children Between 2 to 18" (in en-US). 2021-10-12. https://www.thelivemirror.com/covaxin-approved-for-children-between-2-to-18/. 
  32. ↑ Das, Krishna N. (2021-03-01). "Chinese hackers target Indian vaccine makers SII, Bharat Biotech, says security firm" (in en). Reuters. https://www.reuters.com/article/health-coronavirus-india-china-idUSKCN2AT21O. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Company:Bharat_Biotech&oldid=4173154"